Inhibition Of Epirubicin Poly (Butyl Cyanoacrylate Magnetic Nanoparticles On Tumor Growth In Rat Livers: An Experimental Animal Study

It has been reported that adriamycin magnetic nanoparticles can accumulate in tumor sites. The present study investigated the distribution of epirubicin poly (butyl cyanoacrylate) magnetic nanoparticles (EPI-PBCA-MNPS) in rat livers and its targetability. This study also explored whether EPI-PBCA-MNPS could inhibit the growth of orthotopically transplanted tumors of human liver cancer in nude mice under an applied magnetic field. A total of 75 SD rats in three groups were treated, respectively, with tail vein injections of EPI, EPI-PBCA-MNPS, and EPI-PBCA-MNPS, combined with an applied magnetic field (MF). Concentrations of epirubicin in the plasma, livers, hearts, lungs, spleens, and kidneys of SD rats in each group were measured. Results showed that the distribution of epirubicin in liver tissue under the environment of EPI-PBCA-MNPS+MF was highest. Peak concentration of epirubicin was advanced to 5 minutes after drug administration, indicating that EPI-PBCA-MNPS has a high targetability to the liver and the magnetic field plays a role in the orientation distribution of nanoparticles. A total of 40 nude mice were taken to be transplanted orthotopically with fresh human liver cancer in the liver parenchyma, establishing nude mouse models of human liver cancer. They were randomly divided into 4 groups with 10 mice in each group. Mice in the four groups were treated, respectively, with tail vein injections of normal saline (control group), EPI, EPI-PBCA-MNPS, and EPI-PBCA-MNPS, combined with an applied magnetic field. Experimental results showed that EPI-PBCA-MNPS can exert significant tumor inhibitory effects on orthotopically transplanted tumors of human liver cancer in nude mice and expression of proliferating cell nuclear antigens under an external magnetic field. This proves that EPI-PBCA-MNPS+MF can inhibit the cell cycle conversion of human liver cancer cells, in vivo, inhibiting the growth of liver cancer cells.